---
title: "YuYuanTanTian: Which tariffs imposed by the United States on China have been suspended?"
description: "Since February of last year, the tariffs imposed by the United States on China under the International Emergency Economic Powers Act mainly include a 10% \"fentanyl tariff\" and \"reciprocal tariffs\" of "
type: "news"
locale: "en"
url: "https://longbridge.com/en/news/276529459.md"
published_at: "2026-02-22T07:45:33.000Z"
---

# YuYuanTanTian: Which tariffs imposed by the United States on China have been suspended?

> Since February of last year, the tariffs imposed by the United States on China under the International Emergency Economic Powers Act mainly include a 10% "fentanyl tariff" and "reciprocal tariffs" of 10% and 24%. The U.S. executive order states that these tariffs will be "terminated as soon as possible." The ruling by the U.S. Supreme Court means that the relevant IEEPA tariffs will be automatically canceled. Experts indicate that if the U.S. stops or lowers the tariff rates, China may assess and adjust its measures, but if new tariffs are continued to be imposed, China will also consider corresponding countermeasures

Yu Yuantan stated that since February of last year, the new tariffs imposed by the United States on China under the International Emergency Economic Powers Act (IEEPA) mainly consist of two parts. One is the so-called "fentanyl tariff," which currently has a rate of 10% on China; the other is the so-called "reciprocal tariff," which currently applies a 10% rate on China, while the remaining 24% rate is deferred. According to the U.S. executive order, these tariffs implemented under the IEEPA will be "terminated as soon as possible." After the U.S. Supreme Court's ruling, it means that the administrative order to cancel the IEEPA tariffs issued based on the Supreme Court's decision will also apply to the relevant parts of the China-U.S. tariff arrangements, and the IEEPA tariffs on China should be automatically canceled. Cui Fan, who is familiar with international trade negotiations, stated that if the U.S. stops the relevant measures or lowers the tariff rates, China does not rule out the possibility of assessing and adjusting based on actual changes; however, if the U.S. continues to impose new tariffs using other legal tools, China will also evaluate whether to take corresponding measures.

Risk Warning and Disclaimer

The market has risks, and investment should be cautious. This article does not constitute personal investment advice and does not take into account the specific investment goals, financial situation, or needs of individual users. Users should consider whether any opinions, views, or conclusions in this article align with their specific circumstances. Investing based on this is at one's own risk

## Related News & Research

| Title | Description | URL |
|-------|-------------|-----|
| Mawana Sugars Shareholders Clear Amalgamation With Mawana Foods | Mawana Sugars Limited's shareholders have approved the amalgamation of Mawana Foods Private Limited into Mawana Sugars,  | [Link](https://longbridge.com/en/news/276516853.md) |
| Pezeshkian says Iran will not bow to pressure amid US nuclear talks | Feb 21 (Reuters) - Iranian President Masoud Pezeshkian said on Saturday that his country would not bow its head to press | [Link](https://longbridge.com/en/news/276515418.md) |
| ZAWYA-PRESSR: RAK Ports secures landmark investment from APT Global | RAK Ports has signed a memorandum of understanding with APT Global for a significant investment of approximately AED 50  | [Link](https://longbridge.com/en/news/276524541.md) |
| ZAWYA-PRESSR: Baraka Prosperity Partners targets $250mln institutional raise | Baraka Prosperity Partners is seeking to raise $250 million in institutional capital to enhance its healthcare strategy  | [Link](https://longbridge.com/en/news/276524412.md) |
| NEOS Investment Management LLC Reduces Stock Position in Crinetics Pharmaceuticals, Inc. $CRNX | NEOS Investment Management LLC has reduced its stake in Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) by 61.6% in Q3, no | [Link](https://longbridge.com/en/news/276532688.md) |

---

> **Disclaimer**: This article is for reference only and does not constitute any investment advice.